GlassScriptPhysician profile
Aly Husein
NPI 1396307369
$2,753.96
in general payments reported to CMS, 2019-2025
22 companies · $324 in 2025
The $324 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $123 · 2020: $259 · 2021: $1,029 · 2022: $630 · 2023: $106 · 2024: $282 · 2025: $324.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $712.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $712.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $728.94 | 2021-2022 | |
| Abbvie INC. | $268.92 | 2021-2025 | |
| Biohaven Pharmaceuticals, INC. | $250.00 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $234.65 | 2022 | |
| Janssen Pharmaceuticals, INC | $207.73 | 2020-2021 | |
| Pfizer INC. | $154.67 | 2019-2021 | |
| Esperion Therapeutics, INC. | $125.00 | 2020 | |
| Horizon Therapeutics Plc | $124.99 | 2021 | |
| Astellas Pharma US INC | $109.72 | 2023-2025 | Cresemba |
| Novartis Pharmaceuticals Corporation | $95.93 | 2021-2024 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $83.32 | 2024-2025 | Lifevest |
| Stryker Corporation | $70.62 | 2025 | Clottriever Bold Catheter, Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Inari Medical, INC. | $58.90 | 2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Boston Scientific Corporation | $46.37 | 2022 | |
| Mallinckrodt Hospital Products INC. | $42.84 | 2024-2025 | Terlivaz |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $41.86 | 2024 | |
| Csl Behring | $31.46 | 2023 | Kcentra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.32 | 2025 | Jardiance |
| Amarin Pharma, INC. | $16.85 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $15.81 | 2023 | Eliquis |
| Ucb, INC. | $14.54 | 2022 | |
| Lilly USA, LLC | $11.52 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aly Husein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.